Teva appoints two to executive team

Friday, August 3, 2012 11:07 AM

Teva Pharmaceutical, a global pharmaceutical company based in Israel, has appointed Dr. Carlo De Notaristefani as president and CEO of global operations and Aharon (Arik) Yaari as executive vice president of newly created community and institutional affairs.

De Notaristefani has over 25 years of international experience with extensive technical, operational, manufacturing and P&L experience. Most recently, De Notaristefani was at Bristol-Myers Squibb (BMS) where he served as president of technical operations and global support functions. Before joining BMS, he held several senior positions in manufacturing and supply chain at Aventis Pharmaceuticals. Earlier in his career, De Notaristefani held positions at Hoechst Marion Roussel, Marion Merrell Dow and Dow Chemical.

Yaari joined Teva in 1981 and has served as group vice president of global API, and most recently as group vice president of Teva generics systems. In his new position, Yaari will execute on Teva’s global commitment to social responsibility, philanthropy, institutional affairs and academic relations.

Share:          
CWWeekly

January 26

2015 CRO outlook: M&As, IPOs, strategic partnerships and increased eClinical outsourcing expected to continue

IOM, industry stakeholders propose standards, guidelines for open sharing of clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs